More on NVO
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $47.51 |
|
|||
| Open | $46.35 | ||||
| 52 Wk High | $59.00 | ||||
| 52 Wk Low | $32.80 | ||||
| Day High | $46.74 | ||||
| Day Low | $46.04 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 6,217,769 | ||||
- BofA Securities Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Form 6-K NOVO NORDISK A S For: Aug 31
- Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip
- Novo Nordisk seeks China approval for oral Wegovy drug
- Deutsche Bank Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Sell
- PepsiCo Scraps Coverage of Weight-Loss Drugs for Employees - Bloomberg
- Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK275 at JPMorgan
- Novo Resources Releases Updated Corporate Presentation
- Form 6-K NOVO NORDISK A S For: Aug 24
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
Entities mentioned with NVO
- ARK | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Maynard Um | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Options | View Related Stories »
- Show More...
